Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Rutgers Cancer Institute, University of Utah, Huntsman Cancer Institute, University of North Carolina at Chapel Hill, Minnesota Oncology, Mary Crowley Cancer Research Center, University of Louisville, Emory University, Northern California Melanoma Center, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Amgen (United States), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W131280268